- Home
- TXMD vs IGC Comparison
TXMD vs IGC Comparison
Compare TXMD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- IGC
- Stock Information
- Founded
- TXMD 2008
- IGC 2005
- Country
- TXMD United States
- IGC United States
- Employees
- TXMD N/A
- IGC N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- IGC Health Care
- Exchange
- TXMD Nasdaq
- IGC Nasdaq
- Market Cap
- TXMD 17.1M
- IGC 20.2M
- IPO Year
- TXMD N/A
- IGC N/A
- Fundamental
- Price
- TXMD $1.09
- IGC $0.31
- Analyst Decision
- TXMD
- IGC Strong Buy
- Analyst Count
- TXMD 0
- IGC 2
- Target Price
- TXMD N/A
- IGC $3.88
- AVG Volume (30 Days)
- TXMD 66.5K
- IGC 230.9K
- Earning Date
- TXMD 08-11-2025
- IGC 08-07-2025
- Dividend Yield
- TXMD N/A
- IGC N/A
- EPS Growth
- TXMD N/A
- IGC N/A
- EPS
- TXMD N/A
- IGC N/A
- Revenue
- TXMD $1,841,000.00
- IGC $1,236,000.00
- Revenue This Year
- TXMD $427.09
- IGC N/A
- Revenue Next Year
- TXMD N/A
- IGC $16.45
- P/E Ratio
- TXMD N/A
- IGC N/A
- Revenue Growth
- TXMD 53.55
- IGC 1.65
- 52 Week Low
- TXMD $0.70
- IGC $0.25
- 52 Week High
- TXMD $2.44
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- TXMD 38.09
- IGC 49.31
- Support Level
- TXMD $1.07
- IGC $0.30
- Resistance Level
- TXMD $1.22
- IGC $0.32
- Average True Range (ATR)
- TXMD 0.13
- IGC 0.02
- MACD
- TXMD -0.02
- IGC -0.00
- Stochastic Oscillator
- TXMD 19.15
- IGC 20.00
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.